articleThe Lancet OncologyDec 6, 2022BRONZE OA

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

SJStephen JohnstonMTMasakazu ToiJOJoyce O’ShaughnessyPRPriya RastogiMCMario Campone

Royal Marsden NHS Foundation Trust · Kyoto University · +24 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

549
total citations
FWCI
74.19
Percentile
100%
References
31
Citations per year

Authors

24

Topics & keywords

Topics
Keywords
  • Medicine
  • Breast cancer
  • Internal medicine
  • Oncology
  • Interim analysis
  • Axillary lymph nodes
  • Adjuvant therapy
  • Cancer
No related works found for this paper.

Funding